{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:19:02Z","timestamp":1787854742325,"version":"build-2784847793"},"reference-count":36,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"French Medicines Agency","award":["2019S015"],"award-info":[{"award-number":["2019S015"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2024,9,25]]},"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Fluoroquinolones can cause severe collagen-associated adverse effects, potentially impacting the pulmonary connective tissue. We investigated the association between fluoroquinolones and spontaneous pneumothorax.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A case\u2013time\u2013control study was performed using the nationwide French reimbursement healthcare system database (SNDS). Cases were adults \u226518\u2009years admitted for spontaneous pneumothorax between 2017 and 2022. For each case, fluoroquinolone use was compared between the risk period immediately preceding the admission date (days \u221230 to \u22121), and three earlier reference periods (days \u2212180 to \u2212151, \u2212150 to \u2212121, \u2212120 to \u221291), adjusting for time-varying confounders. OR estimates were corrected for potential exposure-trend bias using a reference group without the event (matched on age, sex, chronic obstructive pulmonary disease history, calendar time). Amoxicillin use was studied similarly to control for indication bias.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 246 pneumothorax cases exposed to fluoroquinolones (63.8% men; mean age, 43.0\u00b118.4 years), 63 were exposed in the 30-day risk period preceding pneumothorax and 128 in the reference periods. Of the 3316 amoxicillin cases (72.9% men; mean age, 39.4\u00b117.6 years), 1210 were exposed in the 30-day risk period and 1603 in the reference ones. OR adjusted for exposure-trend and covariates was 1.59 (95% CI 1.14 to 2.22) for fluoroquinolones and 2.25 (2.07 to 2.45) for amoxicillin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>An increased risk of spontaneous pneumothorax was associated with both fluoroquinolone and amoxicillin use, with an even higher association for amoxicillin. This strongly suggests the role of the underlying infections rather than a causal effect of the individual antibiotics and can be considered reassuring regarding a potential lung connective toxicity of fluoroquinolones.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/thorax-2024-221779","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T13:28:34Z","timestamp":1728653314000},"page":"159-166","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Association of fluoroquinolones with the risk of spontaneous pneumothorax: nationwide case\u2013time\u2013control study"],"prefix":"10.1136","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9071-6314","authenticated-orcid":false,"given":"Anne","family":"B\u00e9nard-Laribi\u00e8re","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Bordeaux, INSERM, BPH, team AHeaD, U1219, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Pambrun","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Bordeaux, INSERM, BPH, team AHeaD, U1219, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Kouzan","sequence":"additional","affiliation":[{"name":"Pulmonary Department, Centre Hospitalier Metropole Savoie, Chambery, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Faillie","sequence":"additional","affiliation":[{"name":"CHU Montpellier, Service de Pharmacologie M\u00e9dicale et Toxicologie, Montpellier, France"},{"name":"Universit\u00e9 de Montpellier, INSERM, Institut Desbrest d\u2019\u00c9pid\u00e9miologie et de Sant\u00e9 Publique, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Bezin","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Bordeaux, INSERM, BPH, team AHeaD, U1219, Bordeaux, France"},{"name":"CHU de Bordeaux, Clinical Pharmacology Unit, INSERM, U1219, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Pariente","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Bordeaux, INSERM, BPH, team AHeaD, U1219, Bordeaux, France"},{"name":"CHU de Bordeaux, Clinical Pharmacology Unit, INSERM, U1219, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,10,11]]},"reference":[{"key":"2025081303204696000_80.3.159.1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-206577"},{"key":"2025081303204696000_80.3.159.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.14299"},{"key":"2025081303204696000_80.3.159.3","doi-asserted-by":"publisher","DOI":"10.1378\/chest.92.6.1009"},{"key":"2025081303204696000_80.3.159.4","doi-asserted-by":"publisher","DOI":"10.1159\/000366065"},{"key":"2025081303204696000_80.3.159.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.kjms.2016.10.007"},{"key":"2025081303204696000_80.3.159.6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1212CI"},{"key":"2025081303204696000_80.3.159.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00298-7"},{"key":"2025081303204696000_80.3.159.8","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-201697","article-title":"Spontaneous pneumothorax as manifestation of Marfan syndrome","volume":"2013","author":"Viveiro","year":"2013","journal-title":"BMJ Case Rep"},{"key":"2025081303204696000_80.3.159.9","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00005310"},{"key":"2025081303204696000_80.3.159.10","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-019-00828-z"},{"key":"2025081303204696000_80.3.159.11","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0089-8"},{"key":"2025081303204696000_80.3.159.12","doi-asserted-by":"publisher","DOI":"10.1002\/jor.21196"},{"key":"2025081303204696000_80.3.159.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.12.012"},{"key":"2025081303204696000_80.3.159.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010077","article-title":"Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study","volume":"5","author":"Daneman","year":"2015","journal-title":"BMJ Open"},{"key":"2025081303204696000_80.3.159.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.06.067"},{"key":"2025081303204696000_80.3.159.16","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.5389"},{"key":"2025081303204696000_80.3.159.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k678","article-title":"Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study","volume":"360","author":"Pasternak","year":"2018","journal-title":"BMJ"},{"key":"2025081303204696000_80.3.159.18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.383"},{"key":"2025081303204696000_80.3.159.19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit708"},{"key":"2025081303204696000_80.3.159.20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2015.6205"},{"key":"2025081303204696000_80.3.159.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.10617"},{"key":"2025081303204696000_80.3.159.22","doi-asserted-by":"publisher","DOI":"10.3109\/15376516.2010.529183"},{"key":"2025081303204696000_80.3.159.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2003.08.002"},{"key":"2025081303204696000_80.3.159.24","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2022.13324"},{"key":"2025081303204696000_80.3.159.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2023.01.009"},{"key":"2025081303204696000_80.3.159.26","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/pds.2330","article-title":"When should case-only designs be used for safety monitoring of medical products?","volume":"21 Suppl 1","author":"Maclure","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025081303204696000_80.3.159.27","unstructured":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9 . La consommation des antibiotiques en France de 2000 \u00e0 2020 [Juillet]. 2023. Available: https:\/\/ansm.sante.fr\/actualites\/lansm-publie-un-rapport-sur-la-consommation-des-antibiotiques-entre-2000-et-2020"},{"key":"2025081303204696000_80.3.159.28","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwab110"},{"key":"2025081303204696000_80.3.159.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2010.10.001"},{"key":"2025081303204696000_80.3.159.30","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199505000-00010"},{"key":"2025081303204696000_80.3.159.31","unstructured":"US Food and Drug Administration . FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. 2019. Available: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics"},{"key":"2025081303204696000_80.3.159.32","unstructured":"European Medicines Agency . Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. 2019. Available: https:\/\/www-ema-europa-eu.docelec.u-bordeaux.fr\/en\/documents\/referral\/quinolone-fluoroquinolone-article-31-referral-disabling-potentially-permanent-side-effects-lead_en.pdf"},{"key":"2025081303204696000_80.3.159.33","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.4192"},{"key":"2025081303204696000_80.3.159.34","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.4199"},{"key":"2025081303204696000_80.3.159.35","doi-asserted-by":"publisher","DOI":"10.1007\/s40471-018-0155-y"},{"key":"2025081303204696000_80.3.159.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmr.2023.01.020"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2024-221779","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T10:21:57Z","timestamp":1755080517000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2024-221779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2,17]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1136\/thorax-2024-221779"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2024-221779","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,11]]}}}